Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience

Abstract

HCV treatment became available for all infected patients regardless of their comorbidities, especially for HIV coinfected subjects, leading to an improvement in both clinical and immunological conditions. We retrospectively analyzed a cohort of HIV/HCV coinfected patients treated with DAA therapies; data regarding epidemiological, viral-immunological, and hepatic parameters before and after DAA administration have been collected. Drug-drug interactions between DAA and both antiretroviral therapy and non-ART-drugs were also evaluated; the study showed the efficacy of DAA schedules in HCV eradication also for HIV/HCV patients with multiple comorbidities and assuming many different drugs. Principal issues are still represented by drug interactions, pill burden, and patients’ compliance. These concerns have to be taken into account, especially in HIV patients for whom the immunological state and ART interactions should always be considered.

Corynebacterium striatum Bacteremia during SARS-CoV2 Infection: Case Report, Literature Review, and Clinical Considerations

“…Overall, although the patient that we presented had no relevant immunosuppression diseases [ 33 , 49 , 50 , 51 ], except for cancer diagnosis, she presumably died due to disseminated intravascular coagulation (CID)-like syndrome caused by septic shock. Despite the SARS-CoV2 infection, the patients did not have any lung involvement; however, we could not definitely rule out viral effects such as hyperinflammation and hypercoagulopathy [ 52 , 53 , 54 ].…”

Pain crisis management in a patient with sickle cell disease during SARS‑CoV‑2 infection: A case report and literature review

“…As suggested by guidelines and literature evidence (19,20), an analgesic cocktail was administered, along with RBC exchange to achieve prompt pain control. Moreover, due to the presence of fever along with increased CRP and procalcitonin levels, antibiotic therapy was administered, and cultural tests were performed to rule out and treat bacterial superinfections, whereas viral coinfections, including HIV, HBV and HCV, were already excluded according to protocols (21)(22)(23)(24)(25)(26)(27). Previous research has highlighted the risk of delaying appropriate management during VOCs in patients with SCD (12).…”

HIV Infection Diagnosis in a Late Presenter Patient during a Severe Imported Falciparum Malaria: A Challenging

“…For the patient we described, HIV infection diagnosis was concomitant to severe opportunistic infections, such as bacteremia and candidemia, although successfully treated with appropriate therapies. Malaria and HIV coinfection led to a deeper immunosuppressive condition which often poorly affect the outcome of both the diseases [20], [21], also compromising treatment success of other occurring infections [22], [23]. Moreover, it is also fundamental to screen these patients for other infections, such as HBV [24] and HCV [20], sharing both the ways of transmission and epidemiological characteristics.…”

“…Malaria and HIV coinfection led to a deeper immunosuppressive condition which often poorly affect the outcome of both the diseases [20], [21], also compromising treatment success of other occurring infections [22], [23]. Moreover, it is also fundamental to screen these patients for other infections, such as HBV [24] and HCV [20], sharing both the ways of transmission and epidemiological characteristics.…”